


IN THE CLAIMS

1 (withdrawn). A compound of the formula:



wherein

Z is -C(R₁₈)(R₁₉)- wherein R₁₈ and R₁₉ are hydrogen;

n is 0;

R is -(CH₂)_m-W wherein m is 0 and W is -C(O)₂-G wherein G is hydrogen;

R₁ and R₂ are independently selected from the group consisting of loweralkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy carbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl, alkylsulfonylamidoalkyl, heterocyclic, (heterocyclic)alkyl and (R_{aa})(R_{bb})N-R_{cc}- wherein R_{aa} is aryl or arylalkyl, R_{bb} is hydrogen or alkanoyl and R_{cc} is alkylene; and

R₃ is R₄-C(O)-R₅- wherein R₅ is alkylene and R₄ is selected from the group consisting of


(i) (R₁₁)(R₁₂)N- wherein R₁₁ is hydrogen and R₁₂ is diarylalkyl

and

(ii) (R_{11a})(R_{12a})N-N(H)- wherein R_{11a} and R_{12a} are independently selected from the group consisting of aryl and alkyl;

or a pharmaceutically acceptable salt thereof.

21 (withdrawn). A compound of the formula:



wherein

Z is -C(R₁₈)(R₁₉)- wherein R₁₈ and R₁₉ are hydrogen;

n is 0;

R is -(CH₂)_m-W wherein m is 0 and W is -C(O)₂-G wherein G is hydrogen;

R₁ and R₂ are independently selected from the group consisting of loweralkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl, alkylsulfonylamidoalkyl, heterocyclic, (heterocyclic)alkyl and (R_{aa})(R_{bb})N-R_{cc}- wherein R_{aa} is aryl or arylalkyl, R_{bb} is hydrogen or alkanoyl and R_{cc} is alkylene; and

R₃ is R₄-C(O)-R₅- wherein R₅ is alkylene and R₄ is selected from the group consisting of

(i) (R₁₁)(R₁₂)N- wherein R₁₁ is hydrogen and R₁₂ is diarylalkyl and

(ii) (R_{11a})(R_{12a})N-N(H)- wherein R_{11a} and R_{12a} are independently selected from the group consisting of aryl and alkyl;

or a pharmaceutically acceptable salt thereof.

157 (withdrawn). The compound according to claim 1 wherein R₁ is aryl substituted with one substituent selected from the group consisting of methoxy, methoxyethoxy, and isopropoxyethoxy; R₂ is 1,3-benzodiox-5-yl; R₅ is methylene; and R₁₂ is diarylalkyl wherein each aryl group of the diarylalkyl is substituted with methyl or ethyl.

158 (withdrawn). The compound according to claim 1 wherein R₁ is phenyl substituted with one substituent selected from the group consisting of methoxy, methoxyethoxy, and isopropoxyethoxy; R₂ is 1,3-benzodiox-5-yl; R₅ is methylene; and R₁₂ is diphenylalkyl wherein each phenyl group of the diphenylalkyl is substituted with methyl or ethyl.

159 (withdrawn). The compound according to claim 21 wherein R₁ is aryl substituted with one substituent selected from the group consisting of methoxy, methoxyethoxy, and isopropoxyethoxy; R₂ is 1,3-benzodiox-5-yl; R₅ is methylene; and R₁₂ is diarylalkyl wherein each aryl group of the diarylalkyl is substituted with methyl or ethyl.

160 (withdrawn). The compound according to claim 21 wherein R₁ is phenyl substituted with one substituent selected from the group consisting of methoxy, methoxyethoxy, and isopropoxyethoxy; R₂ is 1,3-benzodiox-5-yl; R₅ is methylene; and R₁₂ is diphenylalkyl wherein each phenyl group of the diphenylalkyl is substituted with methyl or ethyl.

161 (withdrawn). A compound selected from the group consisting of
trans, trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N-((bis-o-tolyl)methyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid,
trans, trans-2-(4-(2-methoxyethoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N-(2,2-dimethyl-1-phenylpropyl)-1-aminocarbonylmethyl)pyrrolidine-3-carboxylic acid,
trans, trans-2-(4-(2-methoxyethoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N-((bis-o-tolyl)methyl)amino)carbonylmethyl)pyrrolidine-3-carboxylic acid,
trans, trans-2-(4-(2-isopropoxyethoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N-(2,2-dimethyl-1-phenylpropyl)-1-amino)carbonylmethyl)pyrrolidine-3-carboxylic acid,
trans, trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N-(3,3-dimethyl-1-phenylbutyl)-1-amino)carbonylmethyl)pyrrolidine-3-carboxylic acid,
trans, trans-2-(4-(2-isopropoxyethoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N-((1-o-touyl)-1-(o-ethylphenyl)methyl)amino)carbonylmethyl)pyrrolidine-3-carboxylic acid,
trans, trans-2-(4-(2-propoxyethoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N-phenyl-N-t-butylhydrazinocarbonylmethyl)pyrrolidine-3-carboxylic acid, and
trans, trans-2-(4-(2-methoxyethoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N-phenyl-N-t-butylhydrazinocarbonylmethyl)pyrrolidine-3-carboxylic acid,

or a pharmaceutically acceptable salt thereof.

162 (withdrawn). A pharmaceutical composition for antagonizing endothelin comprising a therapeutically effective amount of trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

163 (withdrawn). A pharmaceutical composition for treating cancer comprising a therapeutically effective amount of trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

164 (withdrawn). A pharmaceutical composition for treating prostate cancer comprising a therapeutically effective amount of trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

165 (withdrawn). A pharmaceutical composition for treating nociception comprising a therapeutically effective amount of trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

166 (withdrawn). A pharmaceutical composition for treating bone pain associated with bone cancer comprising a therapeutically effective amount of trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

167 (withdrawn). A method for antagonizing endothelin comprising administering to a mammal in need of such treatment a therapeutically effective amount of trans,trans-2-(4-

methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

168 (withdrawn). A method for treating cancer comprising administering to a mammal in need of such treatment a therapeutically effective amount of trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

169 (withdrawn). A method for treating prostate cancer comprising administering to a mammal in need of such treatment a therapeutically effective amount of trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

170 (previously presented). A method for treating nociception comprising administering to a mammal in need of such treatment a therapeutically effective amount of trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

171 (previously presented). A method for treating bone pain associated with bone cancer comprising administering to a mammal in need of such treatment a therapeutically effective amount of trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

172 (withdrawn). A method for antagonizing endothelin comprising administering to a mammal in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

173 (withdrawn). A method for treating cancer comprising administering to a mammal in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

174 (withdrawn). A method for treating prostate cancer comprising administering to a mammal in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

175 (previously presented). A method for treating nociception comprising administering to a mammal in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

176 (previously presented). A method for treating bone pain associated with bone cancer comprising administering to a mammal in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

177 (withdrawn). A pharmaceutical composition for antagonizing endothelin comprising a therapeutically effective amount of (2R,3R,4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

178 (withdrawn). A pharmaceutical composition for treating cancer comprising a therapeutically effective amount of (2R,3R,4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-

yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

179 (withdrawn). A pharmaceutical composition for treating prostate cancer comprising a therapeutically effective amount of (2R,3R,4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

180 (withdrawn). A pharmaceutical composition for treating nociception comprising a therapeutically effective amount of (2R,3R,4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

181 (withdrawn). A pharmaceutical composition for treating bone pain associated with bone cancer comprising a therapeutically effective amount of (2R,3R,4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

182 (withdrawn). A method for antagonizing endothelin comprising administering to a mammal in need of such treatment a therapeutically effective amount of (2R,3R,4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

183 (withdrawn). A method for treating cancer comprising administering to a mammal in need of such treatment a therapeutically effective amount of (2R,3R,4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

184 (withdrawn). A method for treating prostate cancer comprising administering to

a mammal in need of such treatment a therapeutically effective amount of (2R,3R,4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

185 (previously presented). A method for treating nociception comprising administering to a mammal in need of such treatment a therapeutically effective amount of (2R,3R,4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

186 (previously presented). A method for treating bone pain associated with bone cancer comprising administering to a mammal in need of such treatment a therapeutically effective amount of (2R,3R,4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

187 (withdrawn). A method for antagonizing endothelin comprising administering to a mammal in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of (2R,3R,4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

188 (withdrawn). A method for treating cancer comprising administering to a mammal in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of (2R,3R,4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

189 (withdrawn). A method for treating prostate cancer comprising administering to a mammal in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of (2R,3R,4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt

thereof.

190 (previously presented). A method for treating nociception comprising administering to a mammal in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of (2R,3R,4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

191 (previously presented). A method for treating bone pain associated with bone cancer comprising administering to a mammal in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of (2R,3R,4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonylmethyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.